COVID-19
Conditions
Brief summary
Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim
Interventions
DRUGHydroxychloroquine
400mg BD first day then 200 mg BD for 5 days
Sponsors
Samah Lutfy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
Confirmed cases of SARS-CoV-2 by PCR
Exclusion criteria
less than 18 years old known hypersensitivity to the drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| time to viral clearance | 21 days after patients randomization | PCR will be done every 72 h day till 2 consecutive negative PCR tests(24h apart) which is the viral clearance.The time between randomization and viral clearance is the viral clearance time |
| % of mortality | 60 days after randomization | total number of deaths divided by total number of the group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Length of stay | 60 days after randomization | time from patients randomization till discharge |
| time to be afebrile | 60 days after randomization | time from randomization till day of fever subsiding |
| need for mechanical ventilation | 60 days after randomization | %of deteriorated patients necessitates mechanical ventilation |
Countries
Saudi Arabia
Contacts
Primary ContactSamah M Lutfy, MD
Outcome results
None listed